- Perlemuter G, Bejanin H, Fritsch J, et al. Biliary obstruction caused by portal cavernoma: a study of 8 cases. J Hepatol 1996;25:58-63.
19*.Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
- Uflacker R. Applications of percutaneous mechanical thrombectomy in transjugular intrahepatic portosystemic shunt and portal vein thrombosis. Tech Vasc Interv Radiol 2003;6:59-69.
20*.Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001; 27: 362-367
- Schafer C, Zundler J, Bode JC. Thrombolytic therapy in patients with portal vein thrombosis: case report and review of the literature. Eur J Gastroenterol Hepatol 2000;12:1141-1145.
21*.Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88: 3698-3703
- Brink JS, Brown AK, Palmer BA, et al. Portal vein thrombosis after laparoscopy-assisted splenectomy and cholecystectomy. J Pediatr Surg 2003;38:644-647.
22*.Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109: 369-384
- Brearly S, Hawker PC, Dykes PW, et al. A letal complication of peripheral vein vasopressin infusion. Hepatogastroenterol 1985;32:224-225.
23*.Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemos 1998; 79: 706-708
- Janssen HL, van Buuren HR, Leebeek FW, et al. Portal vein thrombosis: causes and treatment. Ned Tijdschr Geneeskd. 1999;143:2037-2041.
24*.De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-3544
- Joh JH, Kim DI. Mesenteric and portal vein thrombosis: treated with early initiation of anticoagulation. Eur J Vasc Endovasc Surg 2005;29:204-208.
25*.Makris M, Rosendaal FR, Preston FE. Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl 1997;740: 9-15
- Webster GJ, Burroughs AK, Riordan SM. Review article: portal vein thrombosis – new insights into aetiology and management. Aliment Pharmacol Ther 2005;21:1-9.
26*.Kottke-Marchant K, Comp P. Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor. Arch Pathol Lab Med 2002; 126:1337-1348
- Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Hemostasis and Thrombosis. 4th Edition, Lippincott, Williams & Wilkins, 2001: 1497-1516
- Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Hemostasis and Thrombosis. 4th Edition, Lippincott, Williams & Wilkins, 2001: 321-335
- Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classifi cation system. Ann Intern Med 2003; 138:128-134
- Goodnight S.H., Feinstein D.I. Update in Hematology. Ann Intern Med 1998;128:545—51.
- Colaizzo D, Amitrano L; Tiscia GL. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007; 5(1):55-61.
- DE Stefano V; Fiorini A; Rossi E. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007; 5(4):708-14.
- Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996; 10: 499-530
- Donati MB. Cancer and thrombosis. Haemostasis 1994; 24:128-131
- Harrington KJ, Bateman AR, Syrigos KN, Rintoul R, Bhidayasiri R, McCormack M, Thomas H. Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis. Ann Oncol 1997; 8: 669-673
- Matei D, Brenner B, Marder VJ. Acquired thrombophilic syndromes. Blood Rev 2001; 15: 31-48
- H. M.l Lederman; E. Fieldston. Splenic and portal vein thrombosis following laparoscopic splenectomy in a pediatric patient with chronic myeloid leukemia. Sao Paulo Med. J. vol.124 no.5 Sгo Paulo 2006.
- Ali Tuzun İNCE et al. Rapid resolution of portal vein thrombosis and noncirrhotic portal hypertension following cyto-reductive therapy in a patient with chronic myeloid leukemia. Turk J Gastroenterol 2003; 14 (2): 141-144
- Randi ML et al. Prevalence of specific thrombotic accidents in patients with thrombocytosis. Haematologia (Budap). 1993;25(3):149-52.
- Delatour HB. Thrombosis of mesenteric veins as a cause of death after splenectomy. Ann Surg 1895;21:24.
- Rattner DW, Ellman L, Warshaw AL. Portal vein thrombosis after elective splenectomy. An underappreciated, potentially lethal syndrome. Arch Surg 1993;128:565–569.
- Broe PJ, Conley CL, Cameron JL. Thrombosis of the portal vein following splenectomy for myeloid metaplasia. Surg Gynecol Obstet 1981;152:488–492.
- Сarrobio A. et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109:2310-2313.
- А.В. Зубарев, И.О. Иваников, О.Ю. Шипов, В.Е. Сюткин. Сублейкемический миелоз, осложненный тромбозом воротной вены: возможности ультразвуковой ангиографии (клиническое наблюдение). Медицинская визуализация, июль-сентябрь 2000, стр. 21-22.
- Mukai HY, Ninomiya H, Mitsuhashi S et al: Thromboembolism in a patient with transient eosinophilia. Ann Hematol, 1996; 72: 93–95
- Slungaard A, Vercelloti GM, Tran T et al: Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest, 1993; 91: 1721
- Vargas CA, Maldonado O, Botero RC et al: Budd-Chiari syndrome associated with the hypereosinophilic syndrome. AJG, 1993; 88: 1802–3
- Walker M: Idiopathic hypereosinophilia associated with hepatic vein thrombosis. Arch Intern Med, 1987; 147: 2220–21
- Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndrome:analysis of fourteen cases with review of the literature. Medicine (Baltimore), 1975; 54: 1–27
- Parrillo JE, Borer JS, Henry WL et al: The cardiovascular manifestations of the hypereosinophilic syndrome. Am J Med, 1979; 67: 572–82
- Spry CJ, Davies J, Tai PC et al: Clinical features of fi fteen patients with the hypereosinophilic syndrome. Q J Med, 1983; 52: 1–22
- Kikuchi K, Minami K, Miyakawa H, Ishibashi M: Portal vein thrombosis in hypereosinophilic syndrome. AJG, 2002; 97: 1274–75
- Jesus Monterrubio Villar, Alberto Cordoba Lopez, Anselmo J. Macayo Sanchez. Idiopathic eosinophilia associated with portal vein and massive thrombosis: successful thrombolysis with streptokinase. Med Sci Monit, 2006; 12(6): CS53-56
- Hiroyuki Kanno, Naohisa Ouchi, Masatoshi Sato, Tsukasa Wada, Takashi Sawai. Hypereosinophilia with systemic thrombophlebitis. J Hum Path, Volume 36, Issue 5, Pages 585-589 (May 2005)
- Guckelberger O, Bechstein WO, Langrehr JM et al: Successful recanalization of late portal vein thrombosis after liver transplantation using systemic low-dose recombinant tissue plasminogen activator. Transpl Int, 1999; 12: 273–77
- Suzuki S, Nakamura S, Baba S et al: Portal vein thrombosis after splenectomy successfully treated by an enormous dosage of fi brinolytic agent in a short period: report of two cases. Surg Today, 1992; 22: 464–69
- Schafer C, Zundler J, Bode JC: Thrombolytic therapy in patients with portal vein thrombosis: case report and review of the literature. Eur J Gastroenterol Hepatol, 2000; 12: 1141–45
- Demertzis S, Ringe B, Gulba D et al: Treatment of portal vein thrombosis by thrombectomy and regional thrombolysis. Surgery, 1994; 115:389–93